Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study

Published 03/11/2022, 13:13
Updated 03/11/2022, 14:41
© Reuters. Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study

  • Biophytis SA (NASDAQ: BPTS) has released the full results from its phase 2-3 COVA study evaluating Sarconeos (BIO101) for COVID-19-related respiratory failure.
  • The study's objective was to investigate the efficacy and safety of Sarconeos (BIO101), 350 mg BID, in hospitalized COVID-19 patients with hypoxemia, at risk of respiratory failure requiring high flow oxygen or mechanical ventilation, and death.
  • On respiratory failure or early death, post-hoc analyses show a significant reduction with Sarconeos (BIO101) in the risk of early death or respiratory failure at day 28 by 45% in the Intent-To-Treat (ITT) population and by 53% in the Per Protocol (PP) population.
  • In the primary analysis, Sarconeos reduced by 39% the risk of respiratory failure or early death at 28 days compared to the placebo.
  • On mortality follow-up over 90 days, the risk of death was reduced with Sarconeos by 43% in the ITT population and 70% in the PP population.
  • Sarconeos (BIO101) has a good safety profile, with a lower proportion of patients with adverse events compared to placebo (57% vs. 64%), in particular, a lower frequency of serious, primarily respiratory, adverse events (25% vs. 31%).
  • The company aims to file for conditional marketing authorization (Europe) and emergency use authorization (U.S., Brazil) as soon as possible in 2023.
  • Price Action: BPTS shares are up 20.3% at $0.71 during the premarket session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.